Cenix signs RNAi research agreement with SYGNIS
Cenix BioScience GmbH announced that it has signed a research agreement with Heidelberg-based SYGNIS Bioscience GmbH & Co. KG. Under the research agreement’s first assignment to advance the SYGNIS KIBRA project, Cenix will apply its long-standing expertise in combining high content screening with gene silencing analyses in cultured human cells, to establish and optimize multi-parametric microscopy-based assays using the Definiens XD image analysis system. Using such assays, Cenix will conduct target validation to prioritize novel therapeutic drug target candidates, thereby accelerating and enriching the SYGNIS drug development pipeline.
“We are delighted to enter into this new relationship with SYGNIS,” noted Dr. Christophe Echeverri, CEO/CSO of Cenix. “This project, and the many others like it now ongoing here and throughout the industry, continue to confirm the unparalleled power of RNAi-based experimentation for not only discovering but also validating and de-risking new candidate drug targets”.
Financial terms were not disclosed.
Organizations
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

Takara Bio and Eppendorf cooperate - Automation of Takara Bio’s Chemistries on Eppendorf’s Automated Pipetting Systems for Significantly Higher Efficiency

A sugar analysis could reveal different types of cancer - In the future, a little saliva may be enough to detect an incipient cancer
Deuterium Depletion: A New Concept in Anticancer Drug Development
Category:Chemotherapeutic_agents
Febit Receives European Patent for Gene Extraction Procedure

Curcumin activates tumor suppressive signaling pathway - Researchers have identified a signaling pathway via which curcumin can suppress the metastasis of colorectal cancer cells
ORYX Successfully Completes Phase I/IIa Trial to Treat HPV-Associated Cancers

Taking antibiotics back in time - “Recreating such an ancient molecule was exhilarating, akin to bringing dinosaurs or wooly mammoths back to life”
Pharming and Swedish Orphan announce publication of randomized clinical trial results with recombinant human C1 inhibitor
Nano shake-up - UD researchers demonstrate that processing can affect size of nanocarriers for targeted drug delivery
